Historical Valuation
Ionis Pharmaceuticals Inc (IONS) is now in the Fair zone, suggesting that its current forward PS ratio of 16.79 is considered Fairly compared with the five-year average of -23.73. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 71.44 to 88.80 according to relative valuation methord.
Relative Value
Fair Zone
71.44-88.80
Current Price：80.05
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Ionis Pharmaceuticals Inc (IONS) has a current Price-to-Book (P/B) ratio of 20.77. Compared to its 3-year average P/B ratio of 15.43 , the current P/B ratio is approximately 34.64% higher. Relative to its 5-year average P/B ratio of 12.69, the current P/B ratio is about 63.64% higher. Ionis Pharmaceuticals Inc (IONS) has a Forward Free Cash Flow (FCF) yield of approximately -2.35%. Compared to its 3-year average FCF yield of -6.39%, the current FCF yield is approximately -63.32% lower. Relative to its 5-year average FCF yield of -3.79% , the current FCF yield is about -38.13% lower.
P/B
Median3y
15.43
Median5y
12.69
FCF Yield
Median3y
-6.39
Median5y
-3.79
Competitors Valuation Multiple
AI Analysis for IONS
The average P/S ratio for IONS competitors is 39.49, providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS.O) exhibits a P/S ratio of 16.79, which is -57.49% above the industry average. Given its robust revenue growth of 17.12%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IONS
1Y
3Y
5Y
Market capitalization of IONS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IONS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IONS currently overvalued or undervalued?
Ionis Pharmaceuticals Inc (IONS) is now in the Fair zone, suggesting that its current forward PS ratio of 16.79 is considered Fairly compared with the five-year average of -23.73. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 71.44 to 88.80 according to relative valuation methord.
What is Ionis Pharmaceuticals Inc (IONS) fair value?
IONS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 71.44 to 88.80 according to relative valuation methord.
How does IONS's valuation metrics compare to the industry average?
The average P/S ratio for IONS's competitors is 39.49, providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS) exhibits a P/S ratio of 16.79, which is -57.49% above the industry average. Given its robust revenue growth of 17.12%, this premium appears unsustainable.
What is the current P/B ratio for Ionis Pharmaceuticals Inc (IONS) as of Jan 09 2026?
As of Jan 09 2026, Ionis Pharmaceuticals Inc (IONS) has a P/B ratio of 20.77. This indicates that the market values IONS at 20.77 times its book value.
What is the current FCF Yield for Ionis Pharmaceuticals Inc (IONS) as of Jan 09 2026?
As of Jan 09 2026, Ionis Pharmaceuticals Inc (IONS) has a FCF Yield of -2.35%. This means that for every dollar of Ionis Pharmaceuticals Inc’s market capitalization, the company generates -2.35 cents in free cash flow.
What is the current Forward P/E ratio for Ionis Pharmaceuticals Inc (IONS) as of Jan 09 2026?
As of Jan 09 2026, Ionis Pharmaceuticals Inc (IONS) has a Forward P/E ratio of -29.54. This means the market is willing to pay $-29.54 for every dollar of Ionis Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ionis Pharmaceuticals Inc (IONS) as of Jan 09 2026?
As of Jan 09 2026, Ionis Pharmaceuticals Inc (IONS) has a Forward P/S ratio of 16.79. This means the market is valuing IONS at $16.79 for every dollar of expected revenue over the next 12 months.